U.S. markets closed
  • S&P 500

    3,841.94
    +73.47 (+1.95%)
     
  • Dow 30

    31,496.30
    +572.16 (+1.85%)
     
  • Nasdaq

    12,920.15
    +196.68 (+1.55%)
     
  • Russell 2000

    2,192.21
    +45.29 (+2.11%)
     
  • Crude Oil

    66.28
    +2.45 (+3.84%)
     
  • Gold

    1,698.20
    -2.50 (-0.15%)
     
  • Silver

    25.30
    -0.17 (-0.65%)
     
  • EUR/USD

    1.1916
    -0.0063 (-0.52%)
     
  • 10-Yr Bond

    1.5540
    +0.0040 (+0.26%)
     
  • GBP/USD

    1.3834
    -0.0060 (-0.43%)
     
  • USD/JPY

    108.3600
    +0.3840 (+0.36%)
     
  • BTC-USD

    49,565.79
    +861.79 (+1.77%)
     
  • CMC Crypto 200

    982.93
    +39.75 (+4.21%)
     
  • FTSE 100

    6,630.52
    -20.36 (-0.31%)
     
  • Nikkei 225

    28,864.32
    -65.78 (-0.23%)
     

Recap: Intellia Therapeutics Q1 Earnings

  • Oops!
    Something went wrong.
    Please try again later.
Benzinga Insights
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

Shares of Intellia Therapeutics (NASDAQ:NTLA) were flat in pre-market trading after the company reported Q1 results.

Quarterly Results

Earnings per share were down 28.57% over the past year to ($0.63), which missed the estimate of ($0.44).

Revenue of $12,916,000 higher by 23.80% year over year, which missed the estimate of $18,140,000.

Guidance

Earnings guidance hasn't been issued by the company for now.

Intellia Therapeutics hasn't issued any revenue guidance for the time being.

Conference Call Details

Date: May 07, 2020

View more earnings on NTLA

Time: 09:05 AM ET

Webcast URL: https://ir.intelliatx.com/events/event-details/intellia-therapeutics-first-quarter-2020-earnings-conference-call

Recent Stock Performance

52-week high: $19.00

52-week low: $9.18

Price action over last quarter: Up 7.12%

Company Description

Intellia Therapeutics Inc is a genome editing company. It is engaged in developing curative therapeutics utilizing a biological tool known as CRISPR/Cas9. Its pipeline includes in vivo development programs targeting genetic diseases, including transthyretin amyloidosis and hereditary angioedema and ex vivo programs targeting Wilms Tumor 1 for acute myeloid leukemia.

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.